Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 1/20 | 0.35 |
| ▸ | ME1 | P48163 | 1/20 | 0.35 |
| ▸ | ME3 | Q16798 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562645 | 0.74 | HDAC6 (0.41) | ME2ME1ME3HDAC3HDAC1 | |
| SCHEMBL7990920 | 0.70 | THRB (0.35) | HDAC3HDAC1HDAC2HDAC6KDM4E | |
| SCHEMBL12294290 | 0.69 | ATM (0.43) | KDM4E | |
| SCHEMBL19232109 | 0.68 | CNR2 (0.42) | — | |
| SCHEMBL12288410 | 0.68 | HDAC6 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19441058 | 0.66 | TAAR1 (0.50) | — | |
| SCHEMBL5777587 | 0.66 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL21789893 | 0.66 | APLNR (0.46) | — | |
| SCHEMBL18519140 | 0.65 | KMT2A (0.45) | CYP19A1 | |
| SCHEMBL15996608 | 0.65 | CNR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | ME2 2972/4885ME1 1916/4885ME3 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.